Disc Medicine Says Phase 3 Bitopertin Trial Met All Endpoints
Disc Medicine said its Phase 3 APOLLO trial of bitopertin met all primary and secondary endpoints. The company plans to resubmit its NDA by the end of 2026, with an FDA decision expected by mid-2027.
Disc Medicine said its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints. The company plans to resubmit its NDA by end-2026, with an FDA decision expected by mid-2027.